Physician profile
Chandler H Park
NPI 1417137365
$660,955.73
in general payments reported to CMS, 2019-2025
47 companies · $208K in 2025
The $208K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,203 · 2020: $9,909 · 2021: $24K · 2022: $74K · 2023: $160K · 2024: $178K · 2025: $208K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $322K · Consulting Fee: $96K · Travel and Lodging: $62K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $53K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $322,215.00 |
| Consulting Fee | $96,158.00 |
| Travel and Lodging | $61,556.83 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $52,917.50 |
| Food and Beverage | $12,738.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $144,243.18 | 2019-2025 | |
| Janssen Biotech, INC. | $108,045.72 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Gilead Sciences, INC. | $94,186.07 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals Lp | $89,526.31 | 2019-2025 | Lynparza, Imfinzi, Movantik |
| Pfizer INC. | $68,139.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $37,876.69 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $37,793.30 | 2019-2025 | Padcev, Xtandi |
| Seagen INC. | $26,692.95 | 2020-2023 | Padcev |
| Exelixis INC. | $12,459.69 | 2021-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $8,603.72 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $8,506.84 | 2019-2025 | |
| Astrazeneca Uk Limited | $5,330.00 | 2025 | Lynparza |
| Ares Trading Sa | $5,100.00 | 2023-2024 | Bavencio |
| Aveo Pharmaceuticals, INC. | $4,766.57 | 2022-2025 | Fotivda |
| Rigel Pharmaceuticals, INC. | $3,371.23 | 2019-2022 |
Show all 43 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandler Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.